Explore more publications!
Laayoune Tech Observer
Got News to Share?

Laayoune Tech Observer: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Laayoune Tech Observer.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 5, 2025

Cycurion, Inc. (NASDAQ: CYCU) Announces $500,000 Common Share Dividend to Be Paid to its Shareholders on or about December 30th
December 5, 2025

Cycurion, Inc. (NASDAQ: CYCU) Announces $500,000 Common Share Dividend to Be Paid to its Shareholders on or about December 30th

Indeterminate GlobeNewswire
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
December 5, 2025

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Indeterminate GlobeNewswire
Accendatech US comments on the recent setback in phase 2 study to evaluate STAT3 as therapeutic target and other drug development strategies such as AI and precision medicine to treat patients with IPF
December 5, 2025

Accendatech US comments on the recent setback in phase 2 study to evaluate STAT3 as therapeutic target and other drug development strategies such as AI and precision medicine to treat patients with IPF

Indeterminate GlobeNewswire
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 5, 2025

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Indeterminate GlobeNewswire
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
December 5, 2025

XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

Indeterminate GlobeNewswire
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
December 5, 2025

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

Indeterminate GlobeNewswire
Paribu has acquired CoinMENA, MENA’s largest local crypto exchange, in a transaction valued at up to USD 240 million
December 5, 2025

Paribu has acquired CoinMENA, MENA’s largest local crypto exchange, in a transaction valued at up to USD 240 million

Indeterminate GlobeNewswire
Strategic Partnership with Leading UAE Family Office to Build a New Growth Engine in the Middle East and North Africa
December 5, 2025

Strategic Partnership with Leading UAE Family Office to Build a New Growth Engine in the Middle East and North Africa

Indeterminate GlobeNewswire
Entro Security Leads Shai Hulud 2.0 Response with Deep Secrets Analysis and Free Exposure Checker
December 5, 2025

Entro Security Leads Shai Hulud 2.0 Response with Deep Secrets Analysis and Free Exposure Checker

Indeterminate GlobeNewswire
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
December 5, 2025

Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad

Indeterminate GlobeNewswire
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
December 5, 2025

New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer

Indeterminate GlobeNewswire
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
December 5, 2025

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

Indeterminate GlobeNewswire
XBP Global Holdings, Inc. Announces 1-for-10 Reverse Stock Split
December 5, 2025

XBP Global Holdings, Inc. Announces 1-for-10 Reverse Stock Split

Indeterminate GlobeNewswire
GeneLife Expands GeneAI Forecast With New Cancer Risk Prediction Models
December 5, 2025

GeneLife Expands GeneAI Forecast With New Cancer Risk Prediction Models

Indeterminate GlobeNewswire
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease
December 5, 2025

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease

Indeterminate GlobeNewswire
CPI Aerostructures Announces Dorith Hakim’s Appointment to the Aerospace Industry Association’s Executive Committee
December 5, 2025

CPI Aerostructures Announces Dorith Hakim’s Appointment to the Aerospace Industry Association’s Executive Committee

Indeterminate GlobeNewswire
Vertex and CPA.com Announce AI-Driven Expansion of Tax Compliance Services for Accounting Firms
December 5, 2025

Vertex and CPA.com Announce AI-Driven Expansion of Tax Compliance Services for Accounting Firms

Indeterminate GlobeNewswire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 5, 2025

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Nuvini Founder and CEO Pierre Schurmann Commits $6 Million at Significant Premium to Market Price
December 5, 2025

Nuvini Founder and CEO Pierre Schurmann Commits $6 Million at Significant Premium to Market Price

Indeterminate GlobeNewswire
NordVPN’s Threat Protection Pro™ ranks third in an independent anti-phishing test
December 5, 2025

NordVPN’s Threat Protection Pro™ ranks third in an independent anti-phishing test

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions